Sign up
Pharma Capital

Smith & Nephew buys Rotation Medical for US$125mln

Smith & Nephew will pay US$125mln for Rotation Medical plus up to a further US$85mln over the next five years, contingent on financial performance
shoulder
Rotation’s rotator cuff technology complements Smith & Nephew's shoulder repair technologies

Medical equipment group Smith & Nephew (LON:SN.) has completed the acquisition of Rotation Medical Inc., a US-based developer of tissue-regeneration technology to treat rotator-cuff disease.

Smith & Nephew is to pay US$125mln for Rotation plus up to a further US$85mln over the next five years, contingent on financial performance.

READ: Smith & Nephew says full year growth to be at lower end of guidance range

The company said Rotation’s rotator cuff system is “highly complementary” to its existing portfolio of shoulder repair technologies to supplement repairs of more complex tears.

The procedure involves using a bioinductive implant that helps tendons heal by inducing growth of new tendon-like tissue, enhancing the body’s natural healing response.

It helps prevent tear progression and reduce the incidence of re-tears. 

READ: Smith & Nephew chief executive Olivier Bohuon to step down next year

Smith&Nephew said there are more than 650,000 rotator cuff procedures per year in the US growing at a rate of 5-6% per annum.  The cuff system will be sold through Smith & Nephew's larger sports medicine sales force and the integrated Rotation Medical sales team. 



Register here to be notified of future SN. Company articles
View full SN. profile

Smith & Nephew PLC Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.